STOCK TITAN

BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
BioRestorative Therapies Inc. (NASDAQ:BRTX) insiders, including Dale Broadrick and CEO Lance Alstodt, demonstrate confidence in the company's future by acquiring shares. Insider buying signals positive outlook and sentiment, providing valuable insights for evaluating potential company performance.
Positive
  • None.
Negative
  • None.

MELVILLE, NY / ACCESSWIRE / August 2, 2023 / Valuations, competitive landscape and market opportunity are fundamental characteristics in evaluating investment decisions. Insider buying - the "smart money" - can also be an indicator to evaluate the potential performance of a company. BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative") insiders are expressing their confidence in the company's future. Dale Broadrick, an insider of the company, has demonstrated this faith by acquiring 1,000 shares of BioRestorative. These purchases were made at a price of an average of $2.80 per share on July 27, 2023. As a result, Broadrick now owns a total of 623,404 shares of the company.

BioRestorative Therapies, Inc., Wednesday, August 2, 2023, Press release picture

It is worth noting that this transaction was executed through multiple trades, with prices ranging from $2.75 to $2.85 per share. The reported price of $2.80 represents the weighted average purchase price. Furthermore, the company filed an SEC Form 4 following this transaction. Additionally, the current CEO of BRTX Lance Alstodt recently displayed additional confidence in the company by acquiring 4,200 BRTX shares as well.

Insider stock purchases can provide valuable insights into the overall confidence and sentiment surrounding a company. When insiders - such as executives or employees - purchase shares of their own company, it often indicates a positive outlook on its future performance. Insiders have access to non-public information about the company, including its financial health, product pipeline and business strategies. Therefore, their decision to purchase shares can be seen as a strong vote of confidence in the company's prospects.

BioRestorative is a clinical-stage company specializing in stem cell-based therapies. BioRestorative's leading product and novel drug BRTX-100, is an autologous stem cell product that uses the patient's own stem cells, which are harvested, cultured under hypoxic conditions to maximize cell survivability and then injected directly into the patient's body. BRTX-100 is a non-invasive treatment, and the procedure is a single intradiscal injection that takes approximately 15 minutes.

BRTX-100 is a promising treatment for chronic back pain, as there are limited safety risks, and human data from similar studies show promising results with reduced pain and increased function. For millions of Americans suffering without adequate treatment, BioRestorative's innovative therapies might be the light at the end of the tunnel. BioRestorative's other product - ThermoStem - has also shown promising results in the treatment of obesity and related diseases.

These recent developments highlight the growing interest and confidence among investors in BioRestorative Therapies, Inc. as the company continues to make strides in the biotech industry. BioRestorative seems well-positioned to excel in the stem cell market and become a leading player in a growing market, with the global mesenchymal stem cell market expected to grow at a CAGR of 12.8% from 2023 to 2030.

Read more about BioRestorative's trials and platform technology.

Featured photo by Adam Śmigielski on Unsplash.

Contact Details:

Investor Relations
ir@biorestorative.com

SOURCE: BioRestorative Therapies, Inc.



View source version on accesswire.com:
https://www.accesswire.com/771764/BioRestorative-Therapies-Gains-Additional-Investor-Confidence-As-Insider-Dale-Broadrick-CEO-Lance-Alstodt-Purchase-Thousands-of-Shares

Insider buying, such as the recent acquisitions by Dale Broadrick and CEO Lance Alstodt, signals confidence and positive sentiment within the company. It indicates a positive outlook on future performance and provides valuable insights for evaluating potential company performance.

Insider buying can impact stock performance by signaling confidence and positive sentiment within the company, which can influence investor perception and potentially lead to increased stock value.

Insider stock purchases can provide valuable insights into the overall confidence and sentiment surrounding a company, helping investors gauge the potential future performance and outlook of the company.
BioRestorative Therapies Inc

NASDAQ:BRTX

BRTX Rankings

BRTX Latest News

BRTX Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Biotechnology, Health Technology, Health Services, Medical/Nursing Services
US
Melville

About BRTX

biorestorative therapies, inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • disc/spine program (brtxdisc™): our lead cell therapy candidate, brtx-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. we intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. the brtx-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. in an outpatient procedure, brtx-100 is to be injected by a physician into the patient’s damaged disc. the treatment is intended for patients whose pain has not been alleviated by non-invas